Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy

Haematologica

Volumn 93, Issue 4, 2008, Pages 639-640

  Kabbara, Nabil ^a   Lacroix, Claire ^a   De Latour, Regis Peffault ^a   Socié, Gérard ^a   Ghannoum, Mahmoud ^b   Ribaud, Patricia ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Candida guilliermondii; Candida parapsilosis; Candidemia; Caspofungin; Echinocandin

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; MICAFUNGIN; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ANAMNESIS; ASPERGILLOSIS; BACTEREMIA; BLOOD CULTURE; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; LIVER TOXICITY; MALE; MYCOSIS; SEPTICEMIA; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; FLUCONAZOLE; FUNGEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREMEDICATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 42149158264     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11149     Document Type: Letter

References (10)

1. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760-3.
2. Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006;50:2719-27.
3. Canton E, Peman J, Sastre M, Romero M, Espinel-Ingroff A. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother 2006;50:2829-32.
4. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
5. Kuse ER, Chetchotisakd P, Arns da Cunha C, Ruhnke M, Barrios M, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27.
6. Arrieta AC, Telles Filho F, Berezin E, Freire A, Diekemann-Berndt H. A randomized, double-blind trial comparing micafungin (MCFG) and liposomal amphotericin B (LAMB) in pediatric patients with invasive candidiasis (IC) (Abstract). Paper presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Fransisco, 2006:M-1308b.
7. Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, et al. Caspofungin susceptibility testing of isolates from patients with oesophageal candidiasis or invasive candidiasis: relationship of MICs to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-23.
8. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82.
9. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006;34:345-8.
10. Clinical Laboratory Standards institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-2nd edition document M27-A2. 2002. CLSI/NCCLS, Wayne, PA, USA.